Budenz D L, Barton K, Tseng S C
Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami School of Medicine, Miami, Florida 33136, USA.
Am J Ophthalmol. 2000 Nov;130(5):580-8. doi: 10.1016/s0002-9394(00)00600-0.
To compare the safety and efficacy of human preserved amniotic membrane transplant with conjunctival advancement for repair of late-onset glaucoma filtering bleb leaks.
A prospective, randomized clinical trial compared amniotic membrane transplant with conjunctival advancement in patients with leaking glaucoma filtering blebs. Intraocular pressure, number of glaucoma medications, and reoperation for glaucoma or persistent or recurrent bleb-leak were compared in the two groups. Patients were followed for a minimum of 1 year.
Mean intraocular pressure was the same at 6 (amniotic membrane transplant, 15.4 +/- 4.4, conjunctival advancement 14.1 +/- 6.4, P = 0.6), 12 (amniotic membrane transplant, 15.0 +/- 6.3, conjunctival advancement, 13.2 +/- 6.6, P = 0.5), and 24 (amniotic membrane transplant, 17.2 +/- 7.1, conjunctival advancement, 15.0 +/- 6.3, P = 0.6) months. The mean number of glaucoma medications in use was the same in the two groups at all time intervals. After an average follow-up of 19 months, there were seven failures in the amniotic membrane transplant group (two with persistent leaks that were unresponsive to further suturing, two with late-onset leaks, and three who required repeat glaucoma surgery) and none in the conjunctival advancement group. The cumulative survival rate for amniotic membrane transplant was 81% at 6 months, 74% at 1 year, and 46% at 2 years. The cumulative survival rate was 100% for conjunctival advancement throughout follow-up.
Amniotic membrane transplantation does not offer an effective alternative to conjunctival advancement for repair of leaking glaucoma filtering blebs.
比较人保存羊膜移植与结膜推进术修复迟发性青光眼滤过泡渗漏的安全性和有效性。
一项前瞻性随机临床试验比较了羊膜移植与结膜推进术在青光眼滤过泡渗漏患者中的应用。比较两组患者的眼压、青光眼药物使用数量以及青光眼再次手术或持续性或复发性滤过泡渗漏的情况。患者至少随访1年。
在6个月(羊膜移植组,15.4±4.4;结膜推进术组,14.1±6.4,P = 0.6)、12个月(羊膜移植组,15.0±6.3;结膜推进术组,13.2±6.6,P = 0.5)和24个月(羊膜移植组,17.2±7.1;结膜推进术组,15.0±6.3,P = 0.6)时,两组的平均眼压相同。在所有时间间隔内,两组使用的青光眼药物平均数量相同。平均随访19个月后,羊膜移植组有7例失败(2例持续性渗漏对进一步缝合无反应,2例迟发性渗漏,3例需要再次进行青光眼手术),结膜推进术组无失败病例。羊膜移植的累积生存率在6个月时为81%,1年时为74%,2年时为46%。结膜推进术在整个随访期间的累积生存率为100%。
对于修复渗漏的青光眼滤过泡,羊膜移植不是结膜推进术的有效替代方法。